Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Phase 1 Completed
25 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase 1 Completed
29 enrolled
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Phase 1 Completed
21 enrolled
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Phase 1 Completed
5 enrolled
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Phase 1 Completed
55 enrolled
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
Phase 1 Completed
28 enrolled
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase 1 Completed
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
Phase 1 Completed
26 enrolled
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Phase 1 Completed
16 enrolled
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Phase 1 Completed
31 enrolled
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Phase 1 Completed
26 enrolled
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
Phase 1 Completed
34 enrolled
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase 1 Completed
72 enrolled
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Phase 1 Completed
24 enrolled
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Phase 1 Completed
45 enrolled
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Phase 1 Completed
55 enrolled
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Phase 1 Completed
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Phase 1 Completed
30 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase 1 Completed
36 enrolled
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Phase 1 Completed
30 enrolled
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
Phase 1 Completed
30 enrolled
ABT-751 in Treating Young Patients With Refractory Solid Tumors
Phase 1 Completed
90 enrolled
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
Phase 1 Completed
26 enrolled
Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
Phase 1 Completed
32 enrolled
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
Phase 1 Completed
42 enrolled
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
Phase 1 Completed
53 enrolled
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Phase 1 Completed
28 enrolled